ArticleBMC medical imaging2026
Evaluating the grade and IDH mutation status of gliomas by using intravoxel incoherent motion (IVIM) MRI and DSC perfusion MRI.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the diagnostic performance of intravoxel incoherent motion (IVIM) imaging and DSC perfusion MRI to predict the IDH mutation status of gliomas and differentiate high-grade gliomas (HGG) from low-grade gliomas (LGG).
methodsIn this retrospective study, IVIM parameters, including perfusion fraction (f), tissue diffusion (D), and pseudodiffusion (D*), were obtained using a double exponential IVIM model in 61 patients with a pathological diagnosis of glioma. Imaging was performed on a 3 Tesla MRI scanner using only four b-values (0, 50, 400, and 800 s/mm²). The diagnostic performance of rCBV, f, D, D*, ADC, and age parameters in distinguishing HGG from LGG and predicting IDH mutation status in gliomas was evaluated using ROC curve analysis, and their diagnostic powers were compared using the DeLong test.
resultsrCBV, f, and age were higher in patients with HGG, whereas D and ADC were higher in patients with LGG (p < 0.001). rCBV showed the highest AUC for HGG-LGG differentiation (AUC = 0.983), without statistically significant superiority over f, D, or ADC by DeLong testing. rCBV, f, and age were higher in patients with IDH-wild type (IDH-WT) gliomas, whereas D and ADC values were higher in IDH-mutant type (IDH-MT) gliomas (p < 0.05). D showed the highest observed AUC for predicting IDH mutation status (AUC = 0.894) without statistically significant superiority over rCBV, f, or ADC by DeLong testing.
conclusionsIVIM D obtained from a simplified four-b-value protocol may provide complementary information for predicting IDH mutation status in gliomas. However, these preliminary findings require validation in larger, multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.